Akoya Biosciences, Inc.

NasdaqGS:AKYA Rapport sur les actions

Capitalisation boursière : US$104.6m

Akoya Biosciences Bilan de santé

Santé financière contrôle des critères 2/6

Akoya Biosciences possède un total de capitaux propres de $13.6M et une dette totale de $75.9M, ce qui porte son ratio d'endettement à 556.8%. Son actif total et son passif total sont $130.0M et de $116.3M.

Informations clés

556.8%

Ratio d'endettement

US$75.90m

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$35.90m
Fonds propresUS$13.63m
Total du passifUS$116.34m
Total des actifsUS$129.97m

Mises à jour récentes de la santé financière

Recent updates

Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Nov 19
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Nov 12
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Oct 08
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Jun 27
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

May 10
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de AKYA ( $76.9M ) dépassent ses passifs à court terme ( $28.0M ).

Passif à long terme: Les actifs à court terme de AKYA ( $76.9M ) ne couvrent pas ses passifs à long terme ( $88.3M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de AKYA ( 293.4% ) est considéré comme élevé.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de AKYA a diminué au cours des 5 dernières années.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: AKYA dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: AKYA dispose d'une marge de trésorerie suffisante pour 2.3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 23.4 % chaque année.


Découvrir des entreprises saines